TALASUR trial: a single arm phase II trial assessing efficacy and safety of TALazoparib and Avelumab as maintenance therapy in platinum-Sensitive metastatic or locally advanced URothelial carcinoma

TALASUR trial: a single arm phase II trial assessing efficacy and safety of TALazoparib and Avelumab as maintenance therapy in platinum-Sensitive metastatic or locally advanced URothelial carcinoma

Abstract Background Urothelial carcinoma (UC) is the ninth most commonly diagnosed cancer worldwide, with a 3.8/1 male to female ratio. Platinum-based chemotherapy is the first line standard of care for fit patients with advanced UC. However, despite a response rate (RR) for approximately half of pa...

Full description

Bibliographic Details
Main Authors: Elodie Coquan, Bénédicte Clarisse, Justine Lequesne, Pierre-Emmanuel Brachet, Zoé Nevière, Emeline Meriaux, Isabelle Bonnet, Marie Castera, Nicolas Goardon, Jeremy Boutrois, Romain Travers, Florence Joly, Jean-Michel Grellard, Antoine Thiery-Vuillemin
Format: Article
Language:English
Published: BMC 2022-11-01
Series:BMC Cancer
Subjects:
Urothelial carcinoma
PARP inhibitors
Immune checkpoint inhibitors
Anti–PD-L1
Maintenance treatment
Online Access:https://doi.org/10.1186/s12885-022-10216-z

Internet

https://doi.org/10.1186/s12885-022-10216-z

Similar Items